MUMBAI Drugmaker Ranbaxy Laboratories Ltd (RANB.NS) started recalling 29,790 packs of an allergy-relief medicine in the United States in February, after finding defects in the packaging, the U.S. Food and Drug Administration said.
The loratadine and pseudoephedrine sulphate extended release tablets being recalled carry an expiry date of September 2015, and were manufactured by Ranbaxy's Ohm Labs plant in New Jersey, which is the company's only facility making generics for the United States.
All other Ranbaxy plants, based in India, have been banned from exporting generics to the United States after the FDA found manufacturing quality glitches that the agency believed could compromise the quality of medicines.
Rival Indian drugmaker Sun Pharmaceutical Industries Ltd (SUN.NS) agreed to buy Ranbaxy last month in a $3.2 billion deal, betting it can fix Ranbaxy's problems.
The FDA classified the recall by Ohm Labs as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences.
Ranbaxy did not immediately respond to requests for comment.
(Reporting by Zeba Siddiqui in MUMBAI; Editing by Subhranshu Sahu)
Wall Street flat as investors look for clues on rates
Wall Street was little changed on Tuesday morning as investors looked for catalysts to drive the markets while keeping one eye on clues for the timing of the next interest rate hike.
Gold slips as focus shifts to U.S. payrolls data
LONDON Gold fell on Tuesday after Federal Reserve officials sounded a hawkish note on interest rates, boosting the dollar, while attention turned to U.S. payrolls data this week for further clues on the pace of rate hikes.
Oil prices rise on U.S. weather fears, OPEC speculation
LONDON Oil futures rose on Tuesday supported by production suspensions in the U.S. Gulf due to an expected tropical storm and speculation that producers meeting in Algeria next month will act to prop up prices.